City Therapeutics Raises $200 Million in Upsized US IPO
THE SO WHAT
Early-stage RNAi can still clear public markets at the midpoint of the range—biotech IPOs are reopening for platforms with a crisp story even before late-stage data. If you’re building in therapeutics, the window is shifting from binary ‘open/closed’ to selective access for modality narratives investors understand.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureThe 'blurry' world of defence tech revenue
Defence tech ARR is structurally lumpy—multi-year pilots, milestone-based contracts, and classified budgets make SaaS-style metrics almost meaningless. If you're building or backing in this space, underwrite to program wins and procurement cycles, not logo counts and MRR charts.
Startups & Venture‘I’m 30. I’ve got one more shot’: Reson8’s founder wants to build a European AI giant
The more founders talk about building a 'European AI giant,' the clearer the gap between ambition and regional scale dynamics becomes—talent, capital, and compute are still concentrated elsewhere. If you're operating in Europe, assume cross-border expansion and US/Asia partnerships are part of the plan from day one, not a later stage.
Startups & VentureAustin-based RapidCanvas, which uses agents to help businesses build custom AI tools, raised a ∼$29M Series B led by Vertex Ventures and Hitachi Ventures
A $29M Series B for RapidCanvas is more fuel behind 'AI to build AI'—agentic platforms that promise line-of-business teams custom apps without full-stack ML teams. If you're an enterprise CIO, you now have to decide whether to standardize on one of these meta-builders or double down on internal platform teams before shadow AI proliferates.
Startups & VentureIndia’s Billionaire Family Offices are Betting Big on Homegrown AI Startups
Indian billionaire family offices moving capital into domestic AI startups means more patient, locally informed money backing India-specific data, distribution, and regulatory plays. If you’re building or partnering in India, assume faster-moving local competitors with better capital access and tune your strategy around ecosystem integration, not just export of Western models.